SciSparc Ltd. (SPRC) traded higher in Wednesday's premarket after signing a deal to acquire key endoscopy intellectual property from Xylo Technologies Ltd. The move signals a notable strategic pivot for a company that's spent most of its energy on clinical-stage neuroscience therapies.
SciSparc Shares Jump on Medical Device IP Acquisition
Get SciSparc Alerts
Weekly insights + SMS alerts
Expanding the Playbook
SciSparc signed a binding term sheet to purchase a portfolio of patents, trademarks and technical know-how tied to advanced endoscopic imaging systems. The star of the show is the MUSE platform, a single-use device designed for transoral fundoplication procedures that treat gastroesophageal reflux disease.
Through its majority-held subsidiary NeuroThera Labs Inc., SciSparc has traditionally focused on clinical-stage therapies for neurological conditions. This acquisition pushes the company into procedural technology for gastrointestinal treatment markets, broadening its commercial footprint beyond drug development.
The GERD Opportunity
The MUSE device supports minimally invasive treatment for GERD patients, a condition that affects millions globally. SciSparc's strategy leans on Xylo's track record in Greater China, where the company secured a 2019 licensing deal with a Shanghai-based distributor that brought in $3 million upfront.
Now SciSparc wants to replicate that distribution model through exclusive regional partnerships in North America, Europe and Latin America. The bet is that what worked in China can translate to other major markets.
How They're Paying for It
Under the binding terms, SciSparc will issue equity equal to 19.99% of its outstanding shares upon closing. The company has the option to substitute part or all of that consideration with pre-funded warrants, giving it some flexibility on the capital structure front.
The acquisition hands SciSparc direct ownership of both the technology and the commercialization rights. That control could unlock future licensing revenue streams and supports the company's broader diversification push beyond its neuroscience pipeline.
SPRC Price Action: SciSparc shares were up 29.10% at $3.15 at the time of publication on Wednesday. The stock remains near its 52-week low of $1.75.
More News

Markets Hit New Highs Amid Ceasefire News, But Oil Jumps on Hormuz Tensions
Make This One Trade at 2:59 PM on Friday Afternoon, and you'll Thank Me Monday Morning

Operation 'Economic Fury': U.S. Unleashes Financial Firepower on Iran as Hegseth Delivers 'Choose Wisely' Ultimatum

Oil's At $90, Gas Is Over $4, But These 7 Energy Stocks Are Priced Like The Crisis Is Over

The Nasdaq 100's 12-Day Winning Streak Is a Rare Beast. Here's What History Says About What Comes Next.
Remember Tesla?

U.S. Bancorp Beats Earnings, But Investors Focus on Rising Credit Costs
Chip ETFs Are Back on Top, Powered by the AI Boom and a Nvidia-Led Rally
Get SciSparc Alerts
Real-time alerts on price moves, news, and trading opportunities.
Join 20,000+ investors. No spam, ever.
Featured Articles
View all news
Markets Hit New Highs Amid Ceasefire News, But Oil Jumps on Hormuz Tensions
Make This One Trade at 2:59 PM on Friday Afternoon, and you'll Thank Me Monday Morning (Ad)

Operation 'Economic Fury': U.S. Unleashes Financial Firepower on Iran as Hegseth Delivers 'Choose Wisely' Ultimatum

Oil's At $90, Gas Is Over $4, But These 7 Energy Stocks Are Priced Like The Crisis Is Over

The Nasdaq 100's 12-Day Winning Streak Is a Rare Beast. Here's What History Says About What Comes Next.
Trump's Secret Retirement Fund (Ad)





